大肠癌中EGFR、c-erbB-2及VEGF的表达与临床病理特征的关系

目的研究EGFR、c-erbB-2和VEGF在大肠癌中的表达及其与临床病理特征的关系。方法应用免疫组化Envision方法检测61例大肠癌组织中EGFR、c-erbB-2及VEGF的表达水平。以多重线性回归分析上述基因表达水平与临床病理特征的关系。结果61例大肠癌中EGFR、c-erbB-2和VEGF的阳性表达率分别为49．2%（30／60）、73．8％（45／61）和70．5％（43／61），多因素分析显示它们分别与肿瘤大小，淋巴结、肝脏转移及Dukes分期相关，而与病人的性别和年龄无关。结论EGFR、c-erbB-2及VEGF可作为临床判定大肠癌恶性程度及评估预后的指标，对指导术后化疗或靶向治疗具有一定的意义。

Relationship between Expression of EGFR,c-erbB-2 and VEGF with Clinicopathological Characteristics in Human Colorectal Carcinoma

Objective 　To study the correlation of EGFR、c2erbB22 and VEGF expression in colorectal car2 cinoma and their significances to clinicopathological character. Methods 　We studied the expression level of EGFR、c2erbB22 and VEGF in 61 cases of colorectal carcinoma by Envision method and analysed the correlation of the expression level and colorectal carcinoma clinicopathological character by Multiple linear regression. Results 　The respectively high expression rate of EGFR、c2erbB22 and VEGF was 49. 2 % , 73. 8 % and 70. 5 %. Multiple linear regression shows that the high expression of EGFR、c2erbB22 and VEGF were related with the tumor size 、lymph nodes metastasis、liver metastasis and Dukes’ stages , but not correlated with gender and age. Conclusion 　The result s suggest that the high expression of EGFR、 c2erbB22 and VEGF is an useful tool for providing information about the malignant degree , prognosis , and may be as a gaiding in postoperative chemotherapy selection for patient s with colorectal carcinoma.